Atea Pharmaceuticals (AVIR) vs Eikon Therapeutics (EIKN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eikon Therapeutics is the larger company by market cap ($408.4 million vs $401.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | EIKN |
|---|---|---|
| Share price | $5.01 | $7.54 |
| Market cap | $401.83M | $408.40M |
| 1-day change | -1.18% | +0.40% |
| YTD return | +40.34% | — |
| 1-year return | +68.69% | — |
| 5-year return | -87.25% | — |
| EPS (TTM) | $-2.07 | $-8.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $17.40 |
| 52-week low | $2.87 | $7.02 |
| Distance from 52-week high | -22.33% | -56.67% |
| Analyst consensus | none | none |
| Avg. price target upside | +88.02% | +226.26% |
| Average volume | 298.92K | 485.89K |
| Shares outstanding | 80.20M | 54.17M |
| Employees | 55 | 384 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Healthcare · Biotechnology · 55 employees
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Healthcare · Biotechnology · 384 employees
AVIR vs EIKN FAQ
Which is bigger, Atea Pharmaceuticals or Eikon Therapeutics?
Eikon Therapeutics (EIKN) is larger, with a market capitalization of $408.40M compared with $401.83M for Atea Pharmaceuticals (AVIR).
Are Atea Pharmaceuticals and Eikon Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.